Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

Abstract Background While molecularly targeted therapies and immune checkpoint inhibitors have improved the prognosis of advanced melanoma, biomarkers are required to monitor drug responses. Circulating tumor cells (CTCs) are released from primary and/or metastatic tumors into the peripheral blood....

Full description

Bibliographic Details
Main Authors: Yukiko Kiniwa, Kenta Nakamura, Asuka Mikoshiba, Atsuko Ashida, Yasuyuki Akiyama, Atsushi Morimoto, Ryuhei Okuyama
Format: Article
Language:English
Published: BMC 2021-03-01
Series:BMC Cancer
Subjects:
BRAF
Circulating tumor cell
Melanoma
BRAF/MEK inhibitor
Heterogenous mutation
Online Access:https://doi.org/10.1186/s12885-021-08016-y

Similar Items

Similar Items